MEC Basic Full List View

By pinki@katapult.biz / February 16, 2025

Sequencing Endocrine Therapy and Targeted Agents for the Treatment of Metastatic HR+/HER2- Breast Cancer

Sequencing Endocrine Therapy and Targeted Agents for the Treatment of Metastatic HR+/HER2- Breast Cancer

Noridza Rodriguez-Rivera, MD

Current and Future Directions of Immunotherapy for Breast Cancer

Current and Future Directions of Immunotherapy for Breast Cancer

Avan Armaghani, MD, FACP

Case Presentation: CLL

Case Presentation: CLL

Luis A. Velazquez, MD

Case Presentation: Cellular Therapy CAR-T

Case Presentation: Cellular Therapy CAR-T

Karla J. Feliciano Salvá, MD

Case Presentation: NHL

Case Presentation: NHL

Arnaldo Rojas Figueroa, MD

Case Presentation: Myeloma

Case Presentation: Myeloma

Gabriela Torres, MD

Case Presentation: Acute Leukemia

Case Presentation: Acute Leukemia

William Marrero, MD

Liquid Biopsies to Guide Targeted Therapy

Liquid Biopsies to Guide Targeted Therapy

Bruna Pellini, MD

Addressing Social Determinants of Health (SDOH)

Addressing Social Determinants of Health (SDOH)

Luis E. Raez, MD, FACP

The Challenges of Biosimilars in the Daily Oncology Practice?

The Challenges of Biosimilars in the Daily Oncology Practice?

Dina B. Dumercy McHenry, PharmD, MBA, BCOP

Management of Adverse Events of Check Point Inhibitors (CPI) and Antibody Drug Conjugates (ADC) in Solid Tumors

Management of Adverse Events of Check Point Inhibitors (CPI) and Antibody Drug Conjugates (ADC) in Solid Tumors

Meri Muminovic, MD

AML- Where Are We Now and Where Are We Going

AML- Where Are We Now and Where Are We Going

Catherine Lai MD, MPH

Advancing Precision In Endometrial Carcinoma Molecular Classification And Its Impact On Prognosis And Treatment. Are We Ready

Advancing Precision In Endometrial Carcinoma Molecular Classification And Its Impact On Prognosis And Treatment. Are We Ready

Barbara Goff, MD

Adjuvant Therapy for Renal Cell Carcinoma- Hope or Hype

Adjuvant Therapy for Renal Cell Carcinoma- Hope or Hype

Guru P. Sonpavde

Melanoma- Have we Hit a Plateau or are we Making Progress

Melanoma- Have we Hit a Plateau or are we Making Progress

Sanjiv S. Agarwala

Treating Advanced Or Metastatic Cervical Cancer ADCs, VEGF Inhibitors, And Immunotherapy

Treating Advanced Or Metastatic Cervical Cancer ADCs, VEGF Inhibitors, And Immunotherapy

Don S. Dizon, MD, FACP, FASCO

Immunotherapy For Uterine Cancer New Standards For Upfront Treatment For Advanced Or Recurrent Disease

Immunotherapy For Uterine Cancer New Standards For Upfront Treatment For Advanced Or Recurrent Disease

Ritu Salani, MD, MBA

Controversies In The Management Of Ovarian Cancer A Focus On First Line Treatment

Controversies In The Management Of Ovarian Cancer A Focus On First Line Treatment

Alexander B. Olawaiye, MD, FRCOG, FACOG, FACS

Immunotherapy For Triple Negative Breast Cancer Optimal Chemotherapy Partners, New Directors, And Managing Toxicity

Immunotherapy For Triple Negative Breast Cancer Optimal Chemotherapy Partners, New Directors, And Managing Toxicity

Priyanka Sharma, MD

Advances in the Treatment of High Risk Early Stage Hormone Receptor Positive Breast Cancer

Advances in the Treatment of High Risk Early Stage Hormone Receptor Positive Breast Cancer

William J. Gradishar, MD, FASCO, FACP

Antibody Drug Conjugates- New Directions, New Agents!

Antibody Drug Conjugates- New Directions, New Agents!

William J. Gradishar, MD, FASCO, FACP

Sequencing Endocrine Therapy And Targeted Agents For The Treatment Of Hormone Receptor Positive Metastatic Breast Cancer

Sequencing Endocrine Therapy And Targeted Agents For The Treatment Of Hormone Receptor Positive Metastatic Breast Cancer

Komal Jhaveri, MD, FACP

PARP Inhibitors in Prostate Cancer- Who, When, and Why (not)

PARP Inhibitors in Prostate Cancer- Who, When, and Why (not)

Ravi A. Madan, MD

Updates in Systemic Therapy of Urothelial Cancer

Updates in Systemic Therapy of Urothelial Cancer

Ulka Vaishampayan, MD

Small Cell Lung Cancer

Small Cell Lung Cancer

Edgardo S. Santos Castillero, MD, FACP, FASCO

Neoadjuvant and Adjuvant Immunotherapy

Neoadjuvant and Adjuvant Immunotherapy

Luis E. Raez, MD, FACP, FCCP

What’s New in EGFR, ALK, RET and c-MET

What’s New in EGFR, ALK, RET and c-MET

Matthew Gubens, MD, MS

New Agents after Immunotherapy Resistance

New Agents after Immunotherapy Resistance

Paul A. Bunn, MD

New Approaches And Advances In The Therapy Of Gliomas

New Approaches And Advances In The Therapy Of Gliomas

Glenn Lesser, MD, FACP

Immunotherapy in HCC

Immunotherapy in HCC

Rachna T. Shroff, MD, MS, FASCO